Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer

Current Opinion in Investigational Drugs

Volumn 11, Issue 6, 2010, Pages 688-698

  Rosevear, Henry M ^a   Lightfoot, Andrew J ^a   Griffith, Thomas S ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMG 655; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BORTEZOMIB; CARBOPLATIN; CONATUMUMAB; CREATINE KINASE; DEATH RECEPTOR 5; DOXORUBICIN; FLUOROURACIL; GANITUMAB; GEMCITABINE; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; VORINOSTAT;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; GENE EXPRESSION; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HODGKIN DISEASE; HUMAN; HYPOMAGNESEMIA; HYPONATREMIA; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LYMPHOMA; MANTLE CELL LYMPHOMA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PAIN; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; REVIEW; RHINORRHEA; SARCOMA; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SOLID TUMOR; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77952893976     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Cleavage of bid by caspase 8 mediates the mitochondrial damage in the fas pathway of apoptosis. Li H, Zhu H, Xu CJ, Yuan J CELL 1998 94 4 491-501
2. Cytochrome c and dATP-dependent formation of Apaf-1/ caspase-9 complex initiates an apoptotic protease cascade. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang XD CELL 1997 91 4 479-489
3. Safety and antitumor activity of recombinant soluble Apo2 ligand. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L et al J CLIN INvESt 1999 104 2 155-162
4. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225.
5. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC BR J DERMAtOL 2001 144 6 1169-1176
6. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N et al N ENGL J MED 2004 350 23 2335-2342
7. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. Grothey A, Sargent D, Goldberg RM, Schmoll HJ J CLIN ONCOL 2004 22 7 1209-1214
8. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA et al J BIOL CHEM 1998 273 23 14363-14367
9. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E N ENGL J MED 2004 351 4 337-345 (Pubitemid 38944402)
10. Targeting death receptors in cancer with Apo2L/TRAIL. Kelley SK, Ashkenazi A CuRR OpIN pHARMACOL 2004 4 4 333-339
11. Evaluation of the anti-tumor effects of a monoclonal antibody to TRAIL-R2 (DR5) in a patient tumor-SCID mouse model. Suzuki K, Pitoniak R, Goodwin R, Liebowitz D, Repasky EA, Hylander BL pROC AM ASSOC CANCER RES 2003 44 July 11 Abs 2172
12. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ J IMMuNOL 1998 161 6 2833-2840
13. AMG 655, a fully human agonistic antibody against TRAIL receptor-2, induces apoptosis via caspase activation in vitro and in vivo. Kaplan-Lefko P, Gan Y, Huard J, Colloton M, Zoog S, Juan G, Dobson T, Peach M, Pan Y, Kaufman S, Branstetter D et al AM ASSOC CANCER RES ANN MEEt 2007 98 April 17 Abs 4867
14. First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. LoRusso P, Hong D, Heath E, Kurzrock R, Wang D, Hsu M, Goyal L, Wiezorek J, Storgard C, Herbst R J CLIN ONCOL 2007 25 18 Suppl Abs 3534
15. American Society of Clinical Oncology - 43rd Annual Meeting. Research into therapeutics: Part 1. Walker K, Kibble A, Shumoogam J IDRuGS 2007 10 8 513-516 (Pubitemid 47186497)
16. NCT00534027: A phase 1b/2 study of AMG 655 in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer. Amgen Inc CLINICALtRIALS.GOv 2007
17. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang JZ, Hurwitz H J NAtL CANCER INSt 2007 99 16 1232-1239
18. Amgen and Takeda announce exclusive collaboration in Japan on up to 13 Amgen clinical candidates. Amgen Inc pRESS RELEASE 2008 February 04
19. NCT00625651: AMG 655 20060464 colorectal study. Amgen Inc CLINICALtRIALS.GOv 2008
20. NCT00626704: A phase 1b/2 study of AMG 655 in combination with doxorubicin for the first-line treatment of unresectable soft tissue sarcoma. Amgen Inc CLINICALtRIALS.GOv 2008
21. Pharma Japan: Takeda to use Amgen Japan as development subsidiary. Takeda Pharmaceutical Co Ltd pHARMA JpN 2008 2078 February 18 1
22. Launch of Takeda Bio Development Center Limited. Takeda Pharmaceutical Co Ltd pRESS RELEASE 2008 April 01
23. AMG 655, a fully human agonistic antibody against death receptor 5, enhances the anti-tumor activity of gemcitabine in MiaPaCa2/T2, a pancreatic cancer model. Kaplan-Lefko P, Bush T, Belmontes B, Moriguchi J, Dansey M, Osgood T, Canon J, Van Der Vuurst De Vries A-R, Graves J, Branstetter D, Coxon A et al AM ASSOC CANCER RES ANN MEEt 2008 99 April 15 Abs 3999
24. AMG 655, a monoclonal antibody agonist directed against death receptor 5, induces apoptosis in human colon carcinoma cell lines and its therapeutic potential is enhanced in combination with chemotherapeutic agents. Wall J, Colloton M, Huard J, Sevetson B, Huang CP, Pan Y, Gliniak B AM ASSOC CANCER RES ANN MEEt 2008 99 April 13 Abs 1326
25. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F et al J CLIN ONCOL 2008 26 12 2013-2019
26. Takeda company pipeline. Takeda Pharmaceutical Co Ltd COMpANY WORLD WIDE WEB SItE 2008 May 09
27. Measuring Death Receptor 5 (DR5) occupancy in tumors using 64Cu-AMG-655. Hagooly A, Rossin R, Kohno H, Gliniak B, Arroll T, Kaplan-Lefko P, Evelhoch J, Welch M, Hwang D-R J NuCL MED 2008 49 Suppl 1 Abs 1339
28. Characterization of 64Cu-labeled AMG-655 as a PET tracer for imaging Death Receptor 5 (DR5) in tumor. Rossin R, Hagooly A, Kohno H, Arroll T, Gliniak B, Kaplan-Lefko P, Evelhoch J, Welch M, Hwang D-R J NuCL MED 2008 49 Suppl 1 Abs 409
29. NCT00630552: A study of AMG 655 or AMG 479 in combination with gemcitabine for treatment of metastatic pancreatic cancer. Amgen Inc CLINICALtRIALS.GOv 2008
30. Antibodies/antibody conjugates in development. Chang D EORtC-NCI-AACR INt CONGRESS 2008 20 October 24 Abs 464
31. Amgen business review. Amgen Inc COMpANY pRESENtAtION 2008 November 07
32. A phase 1b study of AMG 655 in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer. Paz-Ares L, Torres JMS, Diaz-Padilla I, Links M, Reguart N, Boyer M, Wiezorek J, Sabin T, Hsu M, Van Meerbeeck J ANN ONCOL 2008 19 Suppl 8 Abs 488P
33. A phase 1b study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC). Kindler HL, Garbo L, Stephenson J, Wiezorek J, Sabin T, Hsu M, Civoli F, Richards D J CLIN ONCOL 2009 27 15 Suppl Abs 4501
34. Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC). Saltz L, Infante J, Schwartzberg L, Stephenson J, Rocha-Lima C, Galimi F, Dillingham K, Hsu M, Wiezorek J, Fuchs C J CLIN ONCOL 2009 27 15 Suppl Abs 4079
35. A phase Ib/II trial of AMG 655 and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): Safety results. Rougier P, Infante J, Van Laethem J, Stephenson JJ, Uronis H, Schwartzberg L, Chen L, Wu C, Smethurst D, Peeters M J CLIN ONCOL 2009 27 15 Suppl Ab Abs 4130
36. American Society of Clinical Oncology - 45th Annual Meeting. Part 2. Lakeram M, Kibble A IDRuGS 2009 12 7 404-408
37. Safety and tolerability of conatumumab in combination with bortezomib or vorinostat in patients with relapsed or refractory lymphoma. Younes A, Kirschbaum M, Sokol L, Yee L, Romaguera J, Goyal L, Hsu C-P, Hwang Y, Gorski K, Wong S, Beaupre DM AM SOC HEMAtOL ANN MEEt EXpOSItION 2009 51 December 05 Abs 1708
38. Phase 1 study of conatumumab (AMG 655), a proapoptotic death receptor-5 agonist antibody, in Japanese patients with advanced solid tumors. Murakami H, Yamamoto N, Boku N, Onozawa Y, Doi T, Ohtsu A, Fuse N, Yoshino T, Saito H, Sasaki T, Hsu M et al AACR-NCI-EORtC INt CONGRESS 2009 21 November 18 Abs C6
39. Amgen pipeline. Amgen Inc COMpANY WORLD WIDE WEB SItE 2009 September 03
40. Takeda: Development pipeline as of February 03, 2010. Takeda Pharmaceutical Co Ltd COMpANY WORLD WIDE WEB SItE 2010 February 03
41. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), patients with refractory colorectal cancer. Trarbach T, Moehler M, Heinemann V, Kohne CH, Przyborek M, Schulz C, Sneller V, Gallant G, Kanzler S BR J CANCER 2010 102 3 506-512
42. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Forero-Torres A, Shah J, Wood T, Posey J, Carlisle R, Copigneaux C, Luo F, Wojtowicz-Praga S, Percent I, Saleh M CANCER BIOtHER RADIOpHARM 2010 25 1 13-19
43. Expression of anti-apoptotic factors modulates apo2l/trail resistance in colon carcinoma cells. Lippa MS, Strockbine LD, Le TT, Branstetter DG, Strathdee CA, Holland PM ApOptOSIS 2007 12 8 1465-1478
44. Positron emission tomography (PET) measurement of death receptor 5 (DR5) receptor occupancy (RO) using 64Cu-labeled AMG 655 in Colo205 xenografts. Hwang DR, Rossin R, Gliniak B, Kohno H, Arroll T, Kaplan-Lefko P, Wiezorek J, Friberg G, Radinsky R, Evelhoch J, Welch M AM ASSOC CANCER RES ANN MEEt 2008 Abs 3162
45. Safety and efficacy of AMG 655 in combination with paclitaxel and carboplatin (PC) in patients with advanced non-small cell lung cancer (NSCLC). Paz-Ares L, Sanchez Torres S, Diaz-Padilla I, Links M, Reguart N, Boyer M, Wiezorek J, Sabin T, Pan Y, Van Meerbeeck J CLIN ONCOL 2009 27 Suppl Abs e19048
46. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Kaplan-Lefko PJ, Graves JD, Zoog SJ, Pan Y, Wall J, Branstetter DG, Moriguchi J, Coxon A, Huard JN, Xu R, Peach ML et al CANCER BIOL tHER 2010 9 8 616-629
47. A phase Ib/II study of AMG 655 or AMG 479 in combination with gemcitabine for metastatic pancreatic cancer Kindler HL COMMuNItY ONCOL 2008 5 11 suppl 17 1-4
48. Evaluating the addition of AMG 655 to mFOLFOX6/ bevacizumab in metastatic colorectal cancer. Fuchs CS, Saltz LB COMMuNItY ONCOL 2008 5 10 Suppl 13 1-4
49. Involvement of APO2 ligand/TRAIL in activationinduced death of Jurkat and human peripheral blood T cells. Martinez-Lorenzo MJ, Alava MA, Gamen S, Kim KJ, Chuntharapai A, Pineiro A, Naval J, Anel A EuR J IMMuNOL 1998 28 9 2714-2725
50. Tumor necrosis factor receptor superfamily members and their ligands. Armitage RJ CuRR OpIN IMMuNOL 1994 6 3 407-413
51. Identification and characterization of a new member of the TNF family that induces apoptosis. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG IMMuNItY 1995 3 6 673-682
52. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. Pitt RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A J BIOL CHEM 1996 271 22 12687-12690 (Pubitemid 26175834)
53. Functional analysis of TRAIL receptors using monoclonal antibodies. Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Boiani N, Lynch DH, Smith CA, Goodwin RG, Kubin MZ J IMMuNOL 1999 162 5 2597-2605
54. The novel receptor TRAIL-R4 induces NF-êB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG IMMuNItY 1997 7 6 813-820
55. TRAIL: A molecule with multiple receptors and control mechanisms. Griffith TS, Lynch DH CuRR OpIN IMMuNOL 1998 10 5 559-563
56. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Daniels RA, Turley H, Kimberley FC, Liu XS, Mongkolsapaya J, Ch'En P, Xu XN, Jin BQ, Pezzella F, Screaton GR CELL RES 2005 15 6 430-438
57. Cancer statistics, 2009. Jemal A, Siegel R, Ward E, Hao YP, Xu JQ, Thun MJ CA-A CANCER J CLIN 2009 59 4 225-249
58. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. Meyerhardt JA, Kwok A, Ratain MJ, McGovren JP, Fuchs CS J CLIN ONCOL 2004 22 8 1439-1446
59. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA 3rd, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM et al ANN ONCOL 1996 7 4 347-353
60. Overexpression of pRB in human pancreatic carcinoma cells: Function in chemotherapy-induced apoptosis. Plath T, Peters M, Detjen K, Welzel M, von Marschall Z, Radke C, Wiedenmann B, Rosewicz T J NAtL CANCER INSt 2002 94 2 129-142
61. The IASLC lung cancer staging project: Validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH, Goldstraw P J tHORACIC ONCOL 2007 2 8 694-705 (Pubitemid 47357521)
62. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu JM, Johnson DH N ENGL J MED 2002 346 2 92-98 (Pubitemid 34438899)
63. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM J CLIN ONCOL 2006 24 18 2932-2947
64. The role of neutrophils and TNF-related apoptosis- inducing ligand (TRAIL) in Bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder. HM Rosevear, AJ Lightfoot, MA O'Donnell, TS Griffith CANCER MEtAStASIS REv 2009 28 3-4 345-353
65. Activity of selective fully human agonistic antbodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin-and bortezomib-induced cell death. Georgakis GV, Li Y, Younes M BR J HAEMAtOL 2005 130 501-510
66. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Adams C, Totpal K, Lawrence D, Yee S CELL DEAtH DIFFER 2008 15 751-761
67. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. Soria JC, Smit E, Khayat D, Besse B, Yang XQ, Hsu CP, Reese D, Wiezorek J, Blackhall F J CLIN ONCOL 2010 28 9 1527-1533
68. Amgen global pipeline brochure. Amgen COMpANY WORLD WIDE WEB SItE 2010 February 05
69. Panitumumab: A new frontier of target therapy for the treatment of metastatic colorectal cancer. Addeo R, Caraglia M, Cerbone D, Frega N, Cimmino G, Abbruzzese A, Del Prete S EXpERt REv ANtICANCER tHER 2010 10 4 499-505
70. Phase Ib/II trial of conatumumab and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): Safety and efficacy. Peeters M, Infante JR, Rougier P, Van Laethem J, Uronis HE, Stephenson J, Schwartzberg LS, Chen L, Smethurst D GAStROINtEStINAL CANCERS SYMp 2010 January 22 Abs 443
71. Triggering cell death: The crystal structure of Apo2L/ TRAIL in a complex with death receptor 5. Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF, Ashkenazi A, de Vos AM MOL CELL 1999 4 4 563-571
72. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A IMMuNItY 2000 12 6 611-620
73. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, Walczak H IMMuNItY 2000 12 6 599-609
74. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Du CY, Fang M, Li YC, Li L, Wang XD CELL 2000 102 1 33-42
75. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL CELL 2000 102 1 43-53
76. Apoptosis signaling by death receptors. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME EuR J BIOCHEM 1998 254 3 439-459
77. An antagonist decoy receptor and a death domaincontaining receptor for TRAIL. Pan GH, Ni J, Wei YF, Yu GL, Gentz R, Dixit VM SCIENCE 1997 277 5327 815-818
78. Targeting death and decoy receptors of the tumour- necrosis factor superfamily. Ashkenazi A NAt REv CANCER 2002 2 6 420-430
79. Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? Di Marco M, Di Cicilia R, Macchini M, Nobili E, Vecchiarelli S, Brandi G, Biasco G ONCOL REp 2010 23 5 1183-1192
80. Adjuvant and neoadjuvant therapy in curable pancreatic cancer. Nugent FW, Stuart K SuRG CLIN N AM 2010 90 2 323-339
81. 1096746 Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions. Marini P, Junginger D, Stickl S, Budach W, Niyazi M, Belka C RADIAt ONCOL 2009 4 49
82. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P, Ashkenazi A CuRR BIOL 1997 7 12 1003-1006
83. Ohio Health Care Association elects Dayton Woman as president. Ohio Health Care Association pRESS RELEASE 2010 May 10
84. A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Biven K, Erdal H, Hagg M, Ueno T, Zhou R, Lynch M, Rowley B, Wood J, Zhang C, Toi M, Shoshan MC, Linder S ApOptOSIS 2003 8 3 263-268